# EDGAR Filing Document

**Accession Number:** 0001095565
**File Stem:** 0001437749-25-033632
**Filing Date:** 2025-11
**Character Count:** 107978
**Document Hash:** b78d9f75bd3f77b4a419827a2d7748bb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-033632.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001437749-25-033632

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 54

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HEALTHSTREAM INC
- **CENTRAL INDEX KEY:** 0001095565
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 621443555
- **STATE OF INCORPORATION:** TN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-27701
- **FILM NUMBER:** 251459123

**BUSINESS ADDRESS:**
- **STREET 1:** 500 11TH AVENUE NORTH
- **STREET 2:** SUITE 850
- **CITY:** NASHVILLE
- **STATE:** TN
- **BUSINESS PHONE:** 6153013100

**MAIL ADDRESS:**
- **STREET 1:** 500 11TH AVENUE NORTH
- **STREET 2:** SUITE 850
- **CITY:** NASHVILLE
- **STATE:** TN

?xml version='1.0' encoding='ASCII'? hstm20250930_10q.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

☒ **Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**For the quarterly period ended** September 30, 2025

☐ **Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Commission File No.: 000-27701**

## HealthStream, Inc.
**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **<u>Tennessee</u>** | **<u>62-1443555</u>** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **500 11th Avenue North, Suite 850,** |  |
| **<u>Nashville</u>, <u>Tennessee</u>** | **<u>37203</u>** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**<u>(615) 301-3100</u>**

**(Registrant's telephone number, including area code)**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **<u>Trading Symbol(s)</u>** | **Name of each exchange on which registered** |
| Common Stock (Par Value $0.00) | HSTM | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 3, 2025, there were 29,668,137 shares of the registrant's common stock outstanding.

------

[**Table of Contents**](#toc)

**Index to Form 10**-**Q**

**HEALTHSTREAM, INC.**

---

| | | |
|:---|:---|:---|
|  |  | **Page**<br> **Number** |
| Part I. | [<u>Financial Information</u>](#parti) | [1](#parti) |
| Item 1. | [<u>Financial Statements</u>](#parti) | [1](#parti) |
|  | [<u>Condensed Consolidated Balance Sheets (Unaudited)</u> – <u>September 30, 2025 and December 31, 2024</u>](#parti) | [1](#parti) |
|  | [<u>Condensed Consolidated Statements of Income (Unaudited)</u> – <u>Three and Nine Months ended September 30, 2025 and 2024</u>](#income) | [2](#income) |
|  | [<u>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</u> – <u>Three and Nine Months ended September 30, 2025 and 2024</u>](#compinc) | [3](#compinc) |
|  | [<u>Condensed Consolidated Statement of Shareholders' Equity (Unaudited)</u> – <u>Three and Nine Months ended September 30, 2025 and 2024</u>](#she) | [4](#she) |
|  | [<u>Condensed Consolidated Statements of Cash Flows (Unaudited)</u> – <u>Nine Months ended September 30, 2025 and 2024</u>](#cfs) | [5](#cfs) |
|  | [<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>](#notes) | [6](#notes) |
| Item 2. | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#mda) | [12](#mda) |
| Item 3. | [<u>Quantitative and Qualitative Disclosures about Market Risk</u>](#qqmdr) | [18](#qqmdr) |
| Item 4. | [<u>Controls and Procedures</u>](#cps) | [18](#cps) |
| Part II. | [<u>Other Information</u>](#partii) | [19](#partii) |
| Item 1. | [Legal Proceedings](#Item_1_Legal_Proceedings) | [19](#Item_1_Legal_Proceedings) |
| Item 1A. | [<u>Risk Factors</u>](#risks) | [19](#risks) |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#Item_2_Sales_of_Equity) | [20](#Item_2_Sales_of_Equity) |
| Item 5. | [Other Information](#Item_5_Other_Info) | [20](#Item_5_Other_Info) |
| Item 6. | [<u>Exhibits</u>](#exs) | [21](#exs) |
|  | [<u>SIGNATURE</u>](#sigs) | [22](#sigs) |

---

------

[**Table of Contents**](#toc)

**PART I. FINANCIAL INFORMATION**

**Item 1. *Financial Statements***

**HEALTHSTREAM, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)**

**(In thousands)**

---

| | | |
|:---|:---|:---|
|  | ***September 30,*** | ***December 31,*** |
|  | ***2025*** | ***2024*** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $53544 | $59469 |
| Marketable securities | 39047 | 37748 |
| Accounts receivable, net | 27675 | 30189 |
| Accounts receivable - unbilled | 6047 | 5133 |
| Prepaid and other current assets | 21261 | 20583 |
| Total current assets | 147574 | 153122 |
| Property and equipment, net | 11143 | 10741 |
| Capitalized software development, net | 45699 | 43370 |
| Operating lease right of use assets, net | 15667 | 17453 |
| Goodwill | 191623 | 191220 |
| Intangibles, net | 45369 | 55548 |
| Other assets | 42855 | 39312 |
| Total assets | $499930 | $510766 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $3924 | $6628 |
| Accrued royalties | 5642 | 5190 |
| Accrued liabilities | 10643 | 10141 |
| Accrued compensation | 6600 | 9507 |
| Deferred revenue | 85687 | 84227 |
| Total current liabilities | 112496 | 115693 |
| Deferred tax liabilities | 19671 | 14596 |
| Deferred revenue, noncurrent | 1289 | 1655 |
| Operating lease liability, noncurrent | 15292 | 17366 |
| Other long-term liabilities | 1989 | 2101 |
| Commitments and contingencies |  |  |
| Shareholders' equity: |  |  |
| Preferred Stock, no par value, 10,000 shares authorized, no shares issued or outstanding |  |  |
| Common stock, no par value, 75,000 shares authorized; 29,652 and 30,432 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 228753 | 252432 |
| Retained earnings | 121972 | 108972 |
| Accumulated other comprehensive loss | (1532) | (2049) |
| Total shareholders' equity | 349193 | 359355 |
| Total liabilities and shareholders' equity | $499930 | $510766 |

---

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)**

**(In thousands, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***September 30, 2025*** | ***September 30, 2024*** | ***September 30, 2025*** | ***September 30, 2024*** |
| Revenues, net | $76474 | $73095 | $224355 | $217411 |
| Operating costs and expenses: |  |  |  |  |
| Cost of revenues (excluding depreciation and amortization) | 26507 | 24470 | 78357 | 72825 |
| Product development | 12107 | 12100 | 36228 | 36208 |
| Sales and marketing | 12143 | 11497 | 36101 | 34676 |
| General and administrative | 7330 | 8457 | 23396 | 26325 |
| Depreciation and amortization | 10820 | 10073 | 32441 | 30779 |
| Total operating costs and expenses | 68907 | 66597 | 206523 | 200813 |
| Operating income | 7567 | 6498 | 17832 | 16598 |
| Interest income | 788 | 1007 | 2676 | 2856 |
| Other expense, net | (103) | (26) | (141) | (134) |
| Income before income tax provision | 8252 | 7479 | 20367 | 19320 |
| Income tax provision | 2166 | 1754 | 4559 | 4202 |
| Net income | $6086 | $5725 | $15808 | $15118 |
| Net income per share: |  |  |  |  |
| Basic | $0.20 | $0.19 | $0.52 | $0.50 |
| Diluted | $0.20 | $0.19 | $0.52 | $0.50 |
| Weighted average shares of common stock outstanding: |  |  |  |  |
| Basic | 29688 | 30409 | 30151 | 30374 |
| Diluted | 29811 | 30590 | 30283 | 30512 |
| Dividends declared per share | $0.031 | $0.028 | $0.093 | $0.084 |

---

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)**

**(In thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended*** | ***Three Months Ended*** | ***Nine Months Ended*** | ***Nine Months Ended*** |
|  | ***September 30, 2025*** | ***September 30, 2024*** | ***September 30, 2025*** | ***September 30, 2024*** |
| Net income | $6086 | $5725 | $15808 | $15118 |
| Other comprehensive (loss) income, net of taxes: |  |  |  |  |
| Foreign currency translation adjustments | (293) | 290 | 511 | (229) |
| Unrealized gain on marketable securities | 39 | 43 | 6 | 36 |
| Total other comprehensive (loss) income | (254) | 333 | 517 | (193) |
| Comprehensive income | $5832 | $6058 | $16325 | $14925 |

---

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)**

**(In thousands, except per share data)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Nine Months Ended September 30, 2025*** | ***Nine Months Ended September 30, 2025*** | ***Nine Months Ended September 30, 2025*** | ***Nine Months Ended September 30, 2025*** | ***Nine Months Ended September 30, 2025*** |
|  | ***Common Stock*** | ***Common Stock*** | ***Retained*** | ***Accumulated Other Comprehensive*** | ***Total Shareholders'*** |
|  | ***Shares*** | ***Amount*** | ***Earnings*** | ***(Loss)/Income*** | ***Equity*** |
| Balance at December 31, 2024 | 30432 | $252432 | $108972 | $(2049) | $359355 |
| Net income | *—* |  | 4332 |  | 4332 |
| Comprehensive income | *—* |  |  | 30 | 30 |
| Dividends declared on common stock ($0.031 per share) | *—* |  | (943) |  | (943) |
| Stock-based compensation | *—* | 1104 |  |  | 1104 |
| Common stock issued under stock plans, net of shares withheld for employee taxes | 93 | (1070) | *—* |  | (1070) |
| Balance at March 31, 2025 | 30525 | $252466 | $112361 | $(2019) | $362808 |
| Net income | *—* |  | 5389 |  | 5389 |
| Comprehensive income | *—* |  |  | 741 | 741 |
| Dividends declared on common stock ($0.031 per share) | *—* |  | (946) |  | (946) |
| Stock-based compensation | *—* | 836 |  |  | 836 |
| Common stock issued under stock plans, net of shares withheld for employee taxes | 22 | (5) |  |  | (5) |
| Excise tax on repurchases of common stock | *—* | (135) |  |  | (135) |
| Repurchases of common stock | (650) | (18121) |  |  | (18121) |
| Balance at June 30, 2025 | 29897 | $235041 | $116804 | $(1278) | $350567 |
| Net income | *—* |  | 6086 |  | 6086 |
| Comprehensive loss | *—* |  |  | (254) | (254) |
| Dividends declared on common stock ($0.031 per share) | *—* |  | (918) |  | (918) |
| Stock-based compensation | *—* | 794 |  |  | 794 |
| Common stock issued under stock plans, net of shares withheld for employee taxes | 11 | (121) |  |  | (121) |
| Excise tax on repurchases of common stock | *—* | (64) |  |  | (64) |
| Repurchases of common stock | (256) | (6897) |  |  | (6897) |
| Balance at September 30, 2025 | 29652 | $228753 | $121972 | $(1532) | $349193 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Nine Months Ended September 30, 2024*** | ***Nine Months Ended September 30, 2024*** | ***Nine Months Ended September 30, 2024*** | ***Nine Months Ended September 30, 2024*** | ***Nine Months Ended September 30, 2024*** |
|  | ***Common Stock*** | ***Common Stock*** | ***Retained*** | ***Accumulated Other Comprehensive*** | ***Total Shareholders'*** |
|  | ***Shares*** | ***Amount*** | ***Earnings*** | ***(Loss)/Income*** | ***Equity*** |
| Balance at December 31, 2023 | 30298 | $249075 | $92368 | $(691) | $340752 |
| Net income | *—* |  | 5227 |  | 5227 |
| Comprehensive loss | *—* |  |  | (481) | (481) |
| Dividends declared on common stock ($0.028 per share) | *—* |  | (849) |  | (849) |
| Stock-based compensation | *—* | 1060 |  |  | 1060 |
| Common stock issued under stock plans, net of shares withheld for employee taxes | 100 | (855) | *—* |  | (855) |
| Balance at March 31, 2024 | 30398 | $249280 | $96746 | $(1172) | $344854 |
| Net income | *—* |  | 4168 |  | 4168 |
| Comprehensive loss | *—* |  |  | (45) | (45) |
| Dividends declared on common stock ($0.028 per share) | *—* |  | (851) |  | (851) |
| Stock-based compensation | *—* | 1094 |  |  | 1094 |
| Common stock issued under stock plans, net of shares withheld for employee taxes | 10 | (6) |  |  | (6) |
| Balance at June 30, 2024 | 30408 | $250368 | $100063 | $(1217) | $349214 |
| Net income | *—* |  | 5725 |  | 5725 |
| Comprehensive income | *—* |  |  | 333 | 333 |
| Dividends declared on common stock ($0.028 per share) | *—* |  | (851) |  | (851) |
| Stock-based compensation | *—* | 1131 |  |  | 1131 |
| Common stock issued under stock plans, net of shares withheld for employee taxes | 7 | (71) |  |  | (71) |
| Balance at September 30, 2024 | 30415 | $251428 | $104937 | $(884) | $355481 |

---

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**

**(In thousands)**

---

| | | |
|:---|:---|:---|
|  | ***Nine Months Ended September 30,*** | ***Nine Months Ended September 30,*** |
|  | ***2025*** | ***2024*** |
| OPERATING ACTIVITIES: |  |  |
| Net income | $15808 | $15118 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| Depreciation and amortization | 32441 | 30779 |
| Stock-based compensation | 2734 | 3285 |
| Amortization of deferred commissions | 9190 | 9060 |
| Provision for credit losses | 568 | 2027 |
| Deferred income taxes | 5055 | (960) |
| Loss on equity method investments | 150 | 150 |
| Other | (1146) | (1205) |
| Changes in operating assets and liabilities: |  |  |
| Accounts and unbilled receivables | 1033 | 4744 |
| Prepaid and other current assets | (180) | 785 |
| Other assets | (11881) | (8995) |
| Accounts payable and accrued expenses | (5192) | (8371) |
| Accrued royalties | 453 | 1266 |
| Deferred revenue | 1094 | (1183) |
| Net cash provided by operating activities | 50127 | 46500 |
| INVESTING ACTIVITIES: |  |  |
| Proceeds from maturities of marketable securities | 41286 | 46170 |
| Purchases of marketable securities | (41434) | (51531) |
| Proceeds from sale of non-marketable equity investments |  | 765 |
| Purchase of other investments | (1500) |  |
| Payments associated with capitalized software development | (21910) | (20107) |
| Purchases of property and equipment | (3481) | (1198) |
| Net cash used in investing activities | (27039) | (25901) |
| FINANCING ACTIVITIES: |  |  |
| Taxes paid related to net settlement of equity awards | (1196) | (932) |
| Payment of cash dividends | (2809) | (2551) |
| Repurchases of common stock | (25018) |  |
| Net cash used in financing activities | (29023) | (3483) |
| Effect of exchange rate changes on cash and cash equivalents | 10 | 40 |
| Net (decrease) increase in cash and cash equivalents | (5925) | 17156 |
| Cash and cash equivalents at beginning of period | 59469 | 40333 |
| Cash and cash equivalents at end of period | $53544 | $57489 |
| NONCASH INVESTING AND FINANCING ACTIVITIES: |  |  |
| Purchases of property and equipment, accrued but not paid | $181 | $28 |
| Capitalized software development, accrued but not paid | $746 | $583 |

---

See accompanying Notes to the unaudited Condensed Consolidated Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***1.* OVERVIEW AND BASIS OF PRESENTATION**

***Company Overview***

HealthStream provides primarily Software-as-a-Service ("SaaS") based applications for healthcare organizations—all designed to improve business and clinical outcomes by supporting the people who deliver patient care. The Company is focused on helping individuals and organizations in healthcare meet their ongoing learning, clinical development, credentialing, and scheduling needs. The Company also provides its solutions to nursing schools and nursing students.

The Company is organized and operated according to its One HealthStream approach, with its hStream technology platform at the center of that approach. Increasingly, SaaS-based applications in the Company's diverse ecosystem of solutions utilize the Company's proprietary hStream technology platform to enhance the value proposition for customers by creating interoperability with and among other applications. We believe that our single platform strategy, as represented by hStream, is the best way to realize our mission of improving the quality of care by developing the people who deliver care and the best way to create value for our shareholders in the process. As used in this Quarterly Report on Form *10*-Q ("Form *10*-Q"), "HealthStream," "Company," "we," "us," and "our" mean HealthStream, Inc. and its subsidiaries, unless the context indicates otherwise.

***Basis of Presentation***

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States ("US GAAP") for interim financial information and with the instructions to Form *10-Q* and Article *10* of Regulation S-X. Accordingly, condensed consolidated financial statements do *not* include all of the information and footnotes required by US GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated in consolidation and certain prior period amounts have been reclassified to conform to the current period presentation. Operating results for the *three* and *nine* months ended *September 30, 2025* are *not* necessarily indicative of the results that *may* be expected for the year ending *December 31, 2025.*

The Condensed Consolidated Balance Sheet at *December 31, 2024* was derived from the audited Consolidated Financial Statements at that date but does *not* include all of the information and footnotes required by US GAAP for a complete set of financial statements. For further information, refer to the Consolidated Financial Statements and Notes thereto for the year ended *December 31, 2024* (included in the Company's Annual Report on Form *10*-K, filed with the Securities and Exchange Commission on *February 28, 2025).*

***Business Segments***

The Company's chief operating decision maker ("CODM") is its Chief Executive Officer. Since *January 1, 2023,* the Company's business has been organized and managed around a consolidated, enterprise approach, including with regard to technology, operations, accounting, internal reporting (including the nature of information reviewed by the CODM), organization structure, compensation, performance assessment, and resource allocation. The Company's CODM uses consolidated net income to make operating decisions, assess financial performance, and allocate resources. Further, the CODM reviews and utilizes functional expenses (cost of revenues, product development, sales and marketing, general and administrative, and depreciation and amortization) at the consolidated level to manage the Company's operations. Other segment items included in consolidated net income are interest income, other expense, net, and income tax provision, which are reflected in the Condensed Consolidated Statements of Income. Expenditures for additions to long-lived assets for the consolidated entity were $34.2 million and $29.8 million for the *nine* months ended *September 30, 2025* and *2024*, respectively.

***Non-Marketable Equity Investments***

The aggregate carrying amount of non-marketable equity investments accounted for using the measurement alternative for equity investments that do *not* have readily determinable fair values was $1.5 million as of *September 30, 2025* and *December 31, 2024*, which the Company evaluates for impairment at each reporting period. Cumulatively, there have been *no* adjustments recorded due to changes in the fair value of the non-marketable equity investments the Company held as of *September 30, 2025*. The fair value of non-marketable equity investments is *not* estimated if there are *no* identified events or changes in circumstances that *may* have a significant adverse effect on the fair value of the investment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *6*

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***2.* RECENT ACCOUNTING PRONOUNCEMENTS**

In *November 2023,* the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") *2023*-*07, Segment Reporting (Topic *280*): Improvements to Reportable Segment Disclosures*. The new guidance requires disclosures of significant reportable segment expenses that are regularly provided to the CODM and other segment items on an interim and annual basis. Entities with a single reportable segment will also be required to apply the disclosure requirements in ASU *2023*-*07* on an interim and annual basis. ASU *2023*-*07* was effective for the Company for annual periods beginning after *December 15, 2023* and interim periods within fiscal years beginning after *December 15, 2024.* The Company adopted this standard effective *January 1, 2024* using a retrospective method.

In *December 2023,* the FASB issued ASU *2023*-*09, Income Taxes (Topic *740*): Improvements to Income Tax Disclosures*, which requires public entities to provide disclosure of disaggregated information in the entity's tax rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU *2023*-*09* is effective for fiscal years beginning after *December 15, 2024.* The Company is currently evaluating the effect of this standard on its disclosures and will adopt the standard effective for the annual period ending *December 31, 2025.*

In *November 2024,* the FASB issued ASU *2024*-*03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses*, which requires disclosure of disaggregated information about specific categories underlying certain income statement expense line items in the footnotes to the financial statements for both annual and interim periods. This ASU is effective for fiscal years beginning after *December 15, 2026,* and interim reporting periods beginning after *December 15, 2027.* Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard.

In *September 2025,* the FASB issued ASU *2025*-*06, Intangibles*—*Goodwill and Other*—*Internal-Use Software (Subtopic *350*-*40*): Targeted Improvements to the Accounting for Internal-Use Software*, to modernize the accounting guidance for the costs to develop software for internal use. The standard applies to costs incurred to develop or obtain software for internal use. ASU *2025*-*06* amends the existing standard that refers to various stages of a software development project to align better with current software development methods, such as agile development. Under the new standard, entities will commence capitalizing eligible costs when (i) management has authorized and committed to funding the software project, and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. The new standard also supersedes the guidance related to costs incurred to develop a website. ASU *2025*-*06* is effective for annual periods beginning after *December 15, 2027.* The guidance can be applied on a prospective basis, a modified basis for in-process projects, or on a retrospective basis. The Company is currently evaluating the impact of this accounting standard on its consolidated financial statements.

***3.* REVENUE RECOGNITION**

Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services. Revenue is recognized based on the following *five* step model:

• Identification of the contract with a customer

• Identification of the performance obligations in the contract

• Determination of the transaction price

• Allocation of the transaction price to the performance obligations in the contract

• Recognition of revenue when, or as, the Company satisfies a performance obligation

The following table represents revenues disaggregated by revenue source (in thousands). Sales taxes are excluded from revenues.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended September 30,*** | ***Three Months Ended September 30,*** | ***Nine Months Ended September 30,*** | ***Nine Months Ended September 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Subscription services | $73887 | $69918 | $216617 | $209136 |
| Professional services | 2587 | 3177 | 7738 | 8275 |
| Total revenues, net | $76474 | $73095 | $224355 | $217411 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For both the *three* months ended *September 30, 2025* and *2024*, the Company recognized $0.2 million in impairment losses on receivables and contract assets arising from the Company's contracts with customers. For the *nine* months ended *September 30, 2025* and *2024*, the Company recognized $0.6 million and $2.0 million in impairment losses on receivables and contract assets arising from the Company's contracts with customers, respectively.

During the *three* months ended *September 30, 2025* and *2024*, the Company recognized revenues of $45.9 million and $45.0 million, respectively, from amounts included in deferred revenue at the beginning of the respective periods. During the *nine* months ended *September 30, 2025* and *2024*, the Company recognized revenues of $81.9 million and $79.4 million, respectively, from the amounts included in deferred revenue at the beginning of the respective periods. As of *September 30, 2025*, approximately $621 million of revenue is expected to be recognized from remaining performance obligations under contracts with customers. The Company expects to recognize revenue related to approximately 39% of these remaining performance obligations over the next 12 months, 67% over the next 24 months, and 85% over the next 36 months, with the remaining amounts recognized thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *7*

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***4.* INCOME TAXES**

Income taxes are accounted for using the asset and liability method, whereby deferred tax assets and liabilities are determined based on the temporary differences between the financial statement and tax bases of assets and liabilities measured at tax rates that will be in effect for the year in which the differences are expected to affect taxable income. The Company computes its interim period provision for income taxes by applying the estimated annual effective tax rate to year-to-date pretax income or loss and adjusts the provision for discrete tax items recorded in the period. The Company's effective tax rate was 22% for both the *nine* months ended *September 30, 2025* and *2024*. The Company's effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, the effect of various permanent tax differences, and recognition of discrete tax items.

On *July 4, 2025,* the federal budget reconciliation legislation, commonly referred to as the One Big Beautiful Bill Act ("OBBB"), was signed into law. The OBBB includes significant changes to federal tax law and other regulatory provisions that *may* impact the Company, including modifications to capitalization of research and development expenses and accelerated fixed asset depreciation. The legislation did *not* have a material impact on the Company's income tax expense during the *three* months ended *September 30, 2025,* and it is *not* expected to materially impact the Company's effective income tax rate for *2025.*

***5.* SHAREHOLDERS' EQUITY**

***Dividends on Common Stock***

During the *nine* months ended *September 30, 2025*, the Company's Board of Directors ("Board") declared the following quarterly dividends under the Company's dividend policy (in thousands, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Dividend Payment Date** | **Dividend Declaration Date** | **Dividend Per Share** | **Record Date** | **Cash Outlay** |
| March 21, 2025 | February 24, 2025 | $0.031 | March 10, 2025 | $943 |
| May 30, 2025 | May 5, 2025 | $0.031 | May 19, 2025 | $946 |
| August 29, 2025 | August 4, 2025 | $0.031 | August 18, 2025 | $919 |

---

Additionally, on *November 3, 2025,* the Board declared a quarterly cash dividend of $0.031 per share, payable on *November 28, 2025* to holders of record on *November 17, 2025.* 

***Stock-Based Compensation***

The Company has stock awards outstanding under its *2016* Omnibus Incentive Plan and *2022* Omnibus Incentive Plan.

***Stock Option Activity***

A summary of stock option activity for the *three* months ended *September 30, 2025* is as follows (in thousands, except weighted-average exercise price).

---

| | | | |
|:---|:---|:---|:---|
|  |  | ***Weighted-*** |  |
|  | ***Common*** | ***Average*** | ***Aggregate*** |
|  | ***Shares*** | ***Exercise Price*** | ***Intrinsic Value*** |
| Outstanding at beginning of period | 90 | $20.34 |  |
| Granted |  |  |  |
| Exercised |  |  |  |
| Expired |  |  |  |
| Forfeited |  |  |  |
| Outstanding at end of period | 90 | $20.34 | $711 |
| Exercisable at end of period | 90 | $20.34 | $711 |

---

The weighted average remaining contractual term of options outstanding at *September 30, 2025* was 5.2 years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***Restricted Share Unit Activity***

A summary of Restricted Share Unit ("RSU") activity for the *three* months ended *September 30, 2025* is as follows (in thousands, except weighted-average grant date fair value):

---

| | | | |
|:---|:---|:---|:---|
|  |  | ***Weighted-*** |  |
|  | ***Number of*** | ***Average Grant Date*** | ***Aggregate*** |
|  | ***RSU's*** | ***Fair Value*** | ***Intrinsic Value*** |
| Outstanding at beginning of period | 485 | $26.46 |  |
| Granted | 40 | 29.00 |  |
| Vested | (15) | 24.60 |  |
| Forfeited | (2) | 24.66 |  |
| Outstanding at end of period | 508 | $26.72 | $16852 |

---

As of *September 30, 2025*, total unrecognized compensation expense related to non-vested RSUs was $6.7 million, net of estimated forfeitures, with a weighted average expense recognition period remaining of 2.7 years.

Total stock-based compensation expense recognized in the Condensed Consolidated Statements of Income is as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended September 30,*** | ***Three Months Ended September 30,*** | ***Nine Months Ended September 30,*** | ***Nine Months Ended September 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Cost of revenues (excluding depreciation and amortization) | $50 | $49 | $154 | $152 |
| Product development | 199 | 200 | 626 | 599 |
| Sales and marketing | 110 | 139 | 363 | 415 |
| General and administrative | 435 | 743 | 1591 | 2119 |
| Total stock-based compensation expense | $794 | $1131 | $2734 | $3285 |

---

***Share Repurchase Plan***

On *May 8, 2025,* the Company announced a share repurchase program approved by the Company's Board of Directors under which the Company was authorized to repurchase up to $25.0 million of its outstanding shares of common stock. Pursuant to this authorization, the Company was authorized to make repurchases in the open market, including under a Rule *10b5*-*1* plan, through privately negotiated transactions, or otherwise. During the *three* and *nine* months ended *September 30, 2025,* the Company repurchased and subsequently retired 255,833 shares and 905,786 shares valued at $6.9 million and $25.0 million, respectively, pursuant to this authorization. This share repurchase program is *no* longer in effect as the maximum dollar amount under this program was expended during the *three* months ended *September 30, 2025* as referenced above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***6.* EARNINGS PER SHARE**

Basic earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the net income available to common shareholders for the period by the weighted average number of potentially dilutive common and common equivalent shares outstanding during the period. Common equivalent shares are composed of incremental common shares issuable upon the exercise of stock options and RSUs subject to vesting. The dilutive effect of common equivalent shares is included in diluted earnings per share by application of the treasury stock method. The total number of common equivalent shares excluded from the calculations of diluted earnings per share, due to their anti-dilutive effect or contingent performance conditions, was approximately 224,000 and 177,000 for the *three* months ended *September 30, 2025* and *2024*, respectively, and 171,000 and 169,000 for the *nine* months ended *September 30, 2025* and *2024*.

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended September 30,*** | ***Three Months Ended September 30,*** | ***Nine Months Ended September 30,*** | ***Nine Months Ended September 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Numerator: |  |  |  |  |
| Net income | $6086 | $5725 | $15808 | $15118 |
| Denominator: |  |  |  |  |
| Weighted-average shares outstanding | 29688 | 30409 | 30151 | 30374 |
| Effect of dilutive shares | 123 | 181 | 132 | 138 |
| Weighted-average diluted shares | 29811 | 30590 | 30283 | 30512 |
| Net income per share: |  |  |  |  |
| Basic | $0.20 | $0.19 | $0.52 | $0.50 |
| Diluted | $0.20 | $0.19 | $0.52 | $0.50 |

---

***7.* MARKETABLE SECURITIES**

The fair value of marketable securities, which were all classified as available for sale and which the Company does *not* intend to sell nor will the Company be required to sell prior to recovery of their amortized cost basis, included the following (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***September 30, 2025*** | ***September 30, 2025*** | ***September 30, 2025*** | ***September 30, 2025*** |
|  | ***Adjusted Cost*** | ***Unrealized Gains*** | ***Unrealized Losses*** | ***Fair Value*** |
| Level 2: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. treasury securities | $39019 | $29 | $(1) | $39047 |
| Total | $39019 | $29 | $(1) | $39047 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***December 31, 2024*** | ***December 31, 2024*** | ***December 31, 2024*** | ***December 31, 2024*** |
|  | ***Adjusted Cost*** | ***Unrealized Gains*** | ***Unrealized Losses*** | ***Fair Value*** |
| Level 2: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; U.S. treasury securities | $37726 | $24 | $(2) | $37748 |
| Total | $37726 | $24 | $(2) | $37748 |

---

The carrying amounts reported in the Condensed Consolidated Balance Sheets approximate fair value based on quoted market prices or alternative pricing sources and models utilizing market observable inputs. As of *September 30, 2025* and *December 31, 2024*, the Company did *not* recognize any allowance for credit impairments on its available for sale securities. All investments in marketable securities are classified as current assets on the Condensed Consolidated Balance Sheets because the underlying securities mature within *one* year from the balance sheet date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

[**Table of Contents**](#toc)

**HEALTHSTREAM, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**

***8.* DEBT**

<u>Revolving Credit Facility</u>

On *October 6, 2023,* the Company entered into an Amended and Restated Revolving Credit Agreement ("Revolving Credit Facility"), amending the Revolving Credit Facility dated as of *November 24, 2014,* as amended, with certain lenders party thereto from time to time, and Truist, as Administrative Agent for the lenders. Under the Revolving Credit Facility, the Company *may* borrow up to $50.0 million, which includes a $5.0 million swingline sub-facility and a $5.0 million letter of credit sub-facility, as well as an accordion feature that allows the Company to increase the Revolving Credit Facility by a total of up to $25.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The Revolving Credit Facility has a maturity date of *October 6, 2026.*

The Company's obligations under the Revolving Credit Facility are unsecured. In addition, if the Company forms or acquires any domestic subsidiaries, the loans and other obligations under the Revolving Credit Facility will be guaranteed by such domestic subsidiaries.

At the Company's election, the borrowings under the Revolving Credit Facility, other than the swingline loans, bear interest at either (*1*) a base rate defined as the highest of (a) the rate which the Administrative Agent announces from time to time as its prime lending rate, as in effect from time to time, or (b) the Federal Funds Rate, as in effect from time to time, plus *one*-half of *one* percent (0.50%) per annum (any changes in such rates to be effective as of the date of any change in such rate), plus in each case an applicable margin that varies with the company's funded debt leverage ratio; or (*2*) a term secured overnight financing rate ("SOFR") defined as the greater of (a)(i) the forward-looking term rate based on SOFR determined as of the reference time for such interest period with a term equivalent to such interest period plus (ii) a term SOFR adjustment equal to 0.10% per annum and (b) zero, plus, in each case, an applicable margin that varies with the Company's consolidated total leverage ratio. The Company's borrowings under the swingline loans bear interest at the base rate plus the applicable margin. The initial applicable margin for base rate loans is 0.50% and the initial applicable margin SOFR loans is 1.50%. The applicable margins will be adjusted quarterly, in each case *two* (*2*) business days after the Administrative Agent's receipt of the Company's quarterly financial statements. The Company is also required to pay a commitment fee accruing on the unused revolving commitment, which fee initially is 20 basis points per annum and a letter of credit fee, accruing at a rate per annum equal to the applicable margin for SOFR loans then in effect on the daily average amount of such lender's letter of credit exposure.

Principal is payable in full at maturity on *October 6, 2026,* and there are *no* scheduled principal payments prior to maturity. Interest on base rate loans and swingline loans is payable quarterly in arrears, and interest on SOFR loans is payable at the end of each interest period, and in the case of interest periods longer than *three* months, on each day which occurs every *three* months after the initial date of such interest period.

The purpose of the Revolving Credit Facility is for general working capital needs, permitted acquisitions (as defined in the Amended and Restated Revolving Credit Agreement), and for stock repurchase and/or redemption transactions that the Company *may* authorize.

In addition, the Revolving Credit Facility required the Company to meet certain financial tests, including, without limitation:

• a funded debt leverage ratio (consolidated debt/consolidated EBITDA) of *not* greater than 3.0 to *1.0;* and

• an interest coverage ratio (consolidated EBITDA/consolidated interest expense) of *not* less than 3.0 to *1.0.*

In addition, the Revolving Credit Facility contains certain customary affirmative and negative covenants that, among other things, restrict additional indebtedness, liens and encumbrances, changes to the character of the Company's business, acquisitions, asset dispositions, mergers and consolidations, sale or discount of receivables, creation or acquisitions of additional subsidiaries, and other matters customarily restricted in such agreements.

As of *September 30, 2025*, the Company was in compliance with all covenants. There were no balances outstanding on the Revolving Credit Facility as of or during the *three* and *nine* months ended *September 30, 2025*.

***9.* SUBSEQUENT EVENT**

On *October 8, 2025,* the Company acquired all of the outstanding equity of *Virsys12,* LLC (*"Virsys12"*), a Brentwood, Tennessee-based healthcare technology company that offers payers and health plans an innovative provider data management suite used for onboarding, credentialing, and network management. The consideration paid at closing for *Virsys12* consisted of approximately *$11.2* million in cash, giving effect to customary purchase price adjustments, and is subject to a post-closing working capital adjustment. In addition, up to an additional $4.0 million in cash *may* be paid over a *three*-year period following closing, contingent upon the achievement of certain financial targets. This acquisition expands the Company's existing provider data management and credentialing solution for payers and health plan enterprises, called Network by HealthStream<sup>TM</sup>, launched *14* months ago, which is a part of its broader, market-leading Credentialing application suite. The acquisition will be accounted for using the acquisition method of business combination under ASC *805, Business Combinations*. The Company will provide preliminary purchase price allocation information and other disclosures required by ASC *805* in our Annual Report on Form *10*-K to be filed for the year ending *December 31, 2025.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

[**Table of Contents**](#toc)

**Item 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations***

**Special Cautionary Notice Regarding Forward**-**Looking Statements**

You should read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and related Notes included elsewhere in this Form 10-Q and our audited Consolidated Financial Statements and the Notes thereto for the year ended December 31, 2024, appearing in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission ("SEC") on February 28, 2025 (the "2024 Form 10-K"). Statements contained in this Form 10-Q that are not historical facts are forward-looking statements that the Company intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Statements that are predictive in nature, that depend on or refer to future events or conditions, or that include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," and similar expressions are forward-looking statements.

The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

In evaluating any forward-looking statement, you should specifically consider the information regarding forward-looking statements set forth above and the risks set forth under the caption Part I, Item 1A. Risk Factors in our 2024 Form 10-K and other disclosures in our 2024 Form 10-K and other filings with the SEC from time to time, as well as other cautionary statements contained elsewhere in this Form 10-Q, including our critical accounting policies and estimates as discussed in this Form 10-Q and our 2024 Form 10-K. We undertake no obligation to update or revise any forward-looking statements. You should read this Form 10-Q with the understanding that our actual future results may be materially different from what we currently expect.

**Business Overview** 

HealthStream provides primarily SaaS based applications for healthcare organizations—all designed to improve business and clinical outcomes by supporting the people who deliver patient care. We are focused on helping individuals and organizations in healthcare meet their ongoing learning, clinical development, credentialing, and scheduling needs. We also provide our solutions to nursing schools and nursing students.

Our business is managed and organized around a single platform strategy, also referred to as our One HealthStream approach. At the center of this single platform strategy is our hStream technology platform. By enabling our applications through hStream, we believe that stand-alone applications, which already provide a powerful value proposition on their own, are beginning to leverage each other to more efficiently and effectively empower our customers to manage their business and improve their outcomes. Further, the Company's internal structure and executive leadership are likewise shaped by the organizing principle of a single platform, including with regard to technology, operations, accounting, internal reporting (including the nature of information reviewed by our key decision makers), organizational structure, compensation, performance assessment, and resource allocation.

Significant financial metrics for the third quarter of 2025 are set forth in the bullets below.

• Revenues of $76.5 million in the third quarter of 2025, up 4.6% from $73.1 million in the third quarter of 2024

• Operating income of $7.6 million in the third quarter of 2025, up 16.5% from $6.5 million in the third quarter of 2024

• Net income of $6.1 million in the third quarter of 2025, up 6.3% from $5.7 million in the third quarter of 2024

• Earnings per share ("EPS") of $0.20 per share (diluted) in the third quarter of 2025, up from $0.19 per share (diluted) in the third quarter of 2024

• Adjusted EBITDA<sup>1</sup> of $19.1 million in the third quarter of 2025, up 7.9% from $17.7 million in the third quarter of 2024

<sup>1</sup> Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this Form 10-Q.

During the first quarter of 2025, we entered into an agreement to sublease a portion of our office space in the Capitol View building in Nashville, Tennessee to optimize our workforce performance to deliver positive results for customers, employees, and shareholders. HealthStream's corporate headquarters remains in Nashville in the Capitol View building, while we continue to hire new employees both locally and nationally to support our growth. The sublease commenced in April 2025 and will expire in October 2031. We recorded sublease income, net of initial direct cost amortization, of $0.8 million and $1.5 million during the three and nine months ended September 30, 2025, respectively. In addition, we expect to record sublease income, net, of approximately $0.8 million during the last three months of 2025 and $3.2 million annually thereafter for the remaining term of the sublease under the caption General and Administrative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12

------

[**Table of Contents**](#toc)

**Recent Developments**

Macroeconomic and other conditions in the U.S. that directly or indirectly impact the healthcare industry are challenging in certain respects and may become more challenging based on recent and contemplated changes to various policies and regulations. While healthcare costs continue to grow, government cuts or reimbursement rate reductions to funding for healthcare organizations, the impact of tariffs on goods and services utilized by healthcare provider organizations, as well as uncertainty surrounding potential policy, regulatory, and economic shifts continue to be challenging for our healthcare customers. In particular, the federal budget reconciliation legislation enacted on July 4, 2025 includes significant policy changes that may adversely impact healthcare provider organizations, including changes that are expected to decrease access to health insurance and result in significant cuts to federal healthcare spending, particularly within the Medicaid program. In addition, the federal government entered into a partial shutdown effective October 1, 2025. Although Medicare and Medicaid reimbursement generally remains available throughout a shutdown, our healthcare customers may experience delays in payment for services rendered and other effects related to government agencies operating at reduced capacity and lack of congressional action on significant issues. We believe that these challenges and uncertainties, particularly among healthcare provider organizations with patient populations more dependent on government-funded reimbursement, have caused, and may in the future cause, some delays in purchasing and non-renewals of existing products and services, particularly in relation to elective or non-mandatory products and services.

Additionally, enhanced premium tax credits for individuals eligible to purchase insurance coverage through federal and state-based health insurance marketplaces are scheduled to expire at the end of 2025, and further extension is uncertain. If these tax credits are not extended, this could reduce insurance coverage levels and indirectly influence customer budgets of our healthcare customers in a manner that adversely impacts us.

Challenges also persist in terms of inflationary pressures, ongoing elevated interest rate levels, lower consumer sentiment levels compared to recent periods, and geopolitical tensions, including various ongoing and threatened conflicts abroad and strained global trade relations. We have experienced in certain recent periods, and believe that many of our customers have experienced, increased labor, supply chain, capital, and other expenditures and budgetary pressures associated with such conditions and challenges. These conditions and challenges impacting the U.S. economy and our customers in the healthcare industry have adversely affected, and may continue to adversely impact, our business and results of operations. Additionally, given our focus on customers in the healthcare industry, adverse developments impacting the healthcare industry, including as a result of the developments described above, may adversely impact our business and financial results, although we are unable to fully assess the extent to which our future results may be impacted by any such developments.

**Key Financial Metrics**

Our management utilizes the following financial metrics in connection with managing our business.

• *Revenues, net*. Revenues, net, reflect income generated by the sales of goods and services related to our operations. Revenues, net, were $76.5 million and $224.4 million for the three and nine months ended September 30, 2025, respectively, compared to $73.1 million and $217.4 million for the three and nine months ended September 30, 2024, respectively. Management utilizes revenue in connection with managing our business and believes that this metric provides useful information to investors as a key indicator of the growth and success of our products.

• *Net Income*. Net income represents revenues, net, less all expenses. Net income was $6.1 million and $15.8 million for the three and nine months ended September 30, 2025, respectively, compared to $5.7 million and $15.1 million for the three and nine months ended September 30, 2024, respectively. Management utilizes net income in connection with managing our business, including with regard to our capital deployment strategies.

• *Adjusted EBITDA*. Adjusted EBITDA, calculated as set forth below under "Reconciliation of Non-GAAP Financial Measures," is utilized by our management in connection with managing our business and provides useful information to investors because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash, and/or non-operating items, as more specifically set forth below, which may not fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to investors to assess the Company's ongoing operations. Additionally, certain short-term cash incentive bonuses and performance-based equity award grants are based, in whole or in part, on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets. Adjusted EBITDA was $19.1 million and $52.9 million for the three and nine months ended September 30, 2025, respectively, compared to $17.7 million and $50.6 million for the three and nine months ended September 30, 2024, respectively.

• *Capital Expenditures*. Capital expenditures represent cash payments incurred for purchases of property and equipment and during the development phase for projects to develop software and content. Capital expenditures were $7.5 million and $25.4 million for the three and nine months ended September 30, 2025, respectively, compared to $6.8 million and $21.3 million for the three and nine months ended September 30, 2024, respectively. Management utilizes this metric in connection with managing the allocation of capitalized expenditures in which the Company invests related to the development of its products and believes that this metric is a key indicator of investment in products relative to their current and expected performance.

**Critical Accounting Policies and Estimates**

See Notes to the Consolidated Financial Statements in our 2024 Form 10-K and the Notes to the Condensed Consolidated Financial Statements herein which contain additional information regarding our accounting policies and other disclosures required by US GAAP. There have been no changes in our critical accounting policies and estimates from those reported in our 2024 Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13

------

[**Table of Contents**](#toc)

**Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024**

*Revenues, net.* Revenues increased $3.4 million, or 5%, to $76.5 million for the three months ended September 30, 2025 from $73.1 million for the three months ended September 30, 2024. Subscription revenues increased $4.0 million, or 6%, and professional services revenues decreased by $0.6 million, or 19%, compared to the third quarter of 2024.

A comparison of revenues by revenue source is as follows (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Three Months Ended September 30,** |
|  | **2025** | **2024** | **Percentage Change** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscription services | $73887 | $69918 | 6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Professional services | 2587 | 3177 | -19% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total revenues, net | $76474 | $73095 | 5% |
| **% of Revenues** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subscription services | 97% | 96% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Professional services | 3% | 4% |  |

---

*Cost of Revenues (excluding Depreciation and Amortization).* Cost of revenues increased $2.0 million, or 8%, to $26.5 million for the three months ended September 30, 2025, from $24.5 million for the three months ended September 30, 2024. Cost of revenues as a percentage of revenues were 35% and 33% for the three months ended September 30, 2025 and 2024, respectively. The increase in amount is primarily associated with investments in several areas of our business, primarily in our platform and SaaS applications, resulting in higher cloud hosting, labor costs, third-party software costs, and royalties.

*Product Development.* Product development expenses were $12.1 million for both the three months ended September 30, 2025 and 2024. Product development expenses as a percentage of revenues were 16% and 17% for the three months ended September 30, 2025 and 2024, respectively.

*Sales and Marketing.* Sales and marketing expenses, including personnel costs, increased $0.6 million, or 6%, to $12.1 million for the three months ended September 30, 2025, from $11.5 million for the three months ended September 30, 2024. Sales and marketing expenses were 16% of revenues for both the three months ended September 30, 2025 and 2024. The increase in amount is primarily due to increased commissions and higher labor costs, partially offset by a decrease in marketing expenses.

*General and Administrative.* General and administrative expenses decreased $1.2 million, or 13%, to $7.3 million for the three months ended September 30, 2025, from $8.5 million for the three months ended September 30, 2024. General and administrative expenses were 10% and 12% of revenues for the three months ended September 30, 2025 and 2024, respectively. The decrease in amount is primarily due to sublease income associated with the office sublease that commenced during the second quarter of 2025 as noted above and a reduction in stock-based compensation expense.

*Depreciation and Amortization.* Depreciation and amortization expense increased $0.7 million, or 7%, to $10.8 million for the three months ended September 30, 2025, from $10.1 million for the three months ended September 30, 2024. This increase in amount is primarily a result of amortization associated with capitalized software.

*Interest Income*. Interest income was $0.8 million and $1.0 million for the three months ended September 30, 2025 and 2024, respectively. This decrease is a result of lower interest rates on invested funds.

*Other Expense, Net*. Other expense, net was $0.1 million and $26,000 for the three months ended September 30, 2025 and 2024, respectively. The change is primarily a result of foreign currency losses.

*Income Tax Provision.* The Company recorded a provision for income taxes of $2.2 million for the three months ended September 30, 2025, compared to $1.8 million for the three months ended September 30, 2024. The Company's effective tax rate was 26% for the three months ended September 30, 2025, compared to 23% for the three months ended September 30, 2024. The Company's effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, the effect of various permanent tax differences, and recognition of discrete tax items.

*Net Income.* Net income was $6.1 million and $5.7 million for the three months ended September 30, 2025 and 2024, respectively. EPS was $0.20 per share (diluted) and $0.19 per share (diluted) for the three months ended September 30, 2025 and 2024, respectively.

Adjusted EBITDA was $19.1 million for the three months ended September 30, 2025, compared to $17.7 million for the three months ended September 30, 2024. See "Reconciliation of Non-GAAP Financial Measures" below for our reconciliation of adjusted EBITDA to the most directly comparable measure under US GAAP and disclosure regarding why we believe adjusted EBITDA provides useful information to investors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14

------

[**Table of Contents**](#toc)

**Nine Months Ended September 30, 2025 Compared to Nine Months Ended September 30, 2024**

*Revenues, net.* Revenues increased $6.9 million, or 3%, to $224.4 million for the nine months ended September 30, 2025 from $217.4 million for the nine months ended September 30, 2024. Subscription revenues increased $7.5 million, or 4%, compared to the nine months ended September 30, 2024. Compared to the nine months ended September 30, 2024, revenues for the nine months ended September 30, 2025 grew by approximately $14.7 million across our portfolio of solutions, partially offset by several factors, including a $5.8 million reduction from attrition in legacy applications, a $1.6 million reduction from customer bankruptcies, and a $0.4 million reduction in perpetual license sales.

A comparison of revenues by revenue source is as follows (in thousands):

---

| | | | |
|:---|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **Percentage Change** |
| Subscription services | $216617 | $209136 | 4% |
| Professional services | 7738 | 8275 | -6% |
| Total revenues, net | $224355 | $217411 | 3% |
| **% of Revenues** |  |  |  |
| Subscription services | 97% | 96% |  |
| Professional services | 3% | 4% |  |

---

*Cost of Revenues (excluding Depreciation and Amortization).* Cost of revenues increased $5.6 million, or 8%, to $78.4 million for the nine months ended September 30, 2025, from $72.8 million for the nine months ended September 30, 2024. Cost of revenues as a percentage of revenues were 35% and 33% for the nine months ended September 30, 2025 and 2024, respectively. The increase in amount is primarily associated with investments in several areas of our business, primarily in our platform and SaaS applications, resulting in higher cloud hosting, third-party software, labor costs, and royalties.

*Product Development.* Product development expenses were $36.2 million for both the nine months ended September 30, 2025 and 2024. Product development expenses as a percentage of revenues were 16% and 17% for the nine months ended September 30, 2025 and 2024, respectively.

*Sales and Marketing.* Sales and marketing expenses, including personnel costs, increased $1.4 million, or 4%, to $36.1 million for the nine months ended September 30, 2025, from $34.7 million for the nine months ended September 30, 2024. Sales and marketing expenses were 16% of revenues for both the nine months ended September 30, 2025 and 2024. The increase in amount is primarily due to higher labor costs and sales commissions, partially offset by a decrease in marketing expenses.

*General and Administrative.* General and administrative expenses decreased $2.9 million, or 11%, to $23.4 million for the nine months ended September 30, 2025, from $26.3 million for the nine months ended September 30, 2024. General and administrative expenses were 10% and 12% of revenues for the nine months ended September 30, 2025 and 2024, respectively. The decrease in amount is primarily due to sublease income associated with the office sublease that commenced during the second quarter of 2025 as noted above, coupled with bad debt expense associated with a customer bankruptcy that occurred during the nine months ended September 30, 2024.

*Depreciation and Amortization.* Depreciation and amortization expense increased $1.6 million, or 5%, to $32.4 million for the nine months ended September 30, 2025, from $30.8 million for the nine months ended September 30, 2024. This increase in amount is primarily a result of amortization associated with capitalized software.

*Interest Income*. Interest income was $2.7 million and $2.9 million for the nine months ended September 30, 2025 and 2024, respectively. This decrease is a result of lower interest rates on invested funds.

*Other Expense, Net*. Other expense, net was $0.1 million for both the nine months ended September 30, 2025 and 2024.

*Income Tax Provision.* The Company recorded a provision for income taxes of $4.6 million and $4.2 million for the nine months ended September 30, 2025 and 2024, respectively. The Company's effective tax rate was 22% for both the nine months ended September 30, 2025 and 2024. The Company's effective tax rate primarily reflects the statutory corporate income tax rate, the net effect of state taxes, foreign income taxes, the effect of various permanent tax differences, and recognition of discrete tax items.

*Net Income.* Net income was $15.8 million and $15.1 million for the nine months ended September 30, 2025 and 2024, respectively. EPS was $0.52 per share (diluted) and $0.50 per share (diluted) for the nine months ended September 30, 2025 and 2024, respectively.

Adjusted EBITDA was $52.9 million for the nine months ended September 30, 2025, compared to $50.6 million for the nine months ended September 30, 2024. See "Reconciliation of Non-GAAP Financial Measures" below for our reconciliation of adjusted EBITDA to the most directly comparable measure under US GAAP and disclosure regarding why we believe adjusted EBITDA provides useful information to investors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15

------

[**Table of Contents**](#toc)

**Reconciliation of Non-GAAP Financial Measures**

This Form 10-Q presents adjusted EBITDA, which is a non-GAAP financial measure used by management in analyzing our financial results and ongoing operational performance.

In order to better assess the Company's financial results, management believes that net income before interest, income taxes, stock-based compensation, depreciation and amortization, and changes in fair value of, including gains (losses) on the sale of, non-marketable equity investments ("adjusted EBITDA") is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash, and/or non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We believe that adjusted EBITDA is useful to investors to assess the Company's ongoing operating performance and to compare the Company's operating performance between periods. Additionally, certain short-term cash incentive bonuses and performance-based equity awards are based on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets.

Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as an analytical tool.

A reconciliation of adjusted EBITDA to the most directly comparable GAAP measure, net income, is set forth below (in thousands).

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| GAAP net income | $6086 | $5725 | $15808 | $15118 |
| Interest income | (788) | (1007) | (2676) | (2856) |
| Interest expense | 26 | 26 | 76 | 75 |
| Income tax provision | 2166 | 1754 | 4559 | 4202 |
| Stock-based compensation expense | 794 | 1131 | 2734 | 3285 |
| Depreciation and amortization | 10820 | 10073 | 32441 | 30779 |
| Adjusted EBITDA | $19104 | $17702 | $52942 | $50603 |

---

**Liquidity and Capital Resources** 

Net cash provided by operating activities increased by $3.6 million to $50.1 million during the nine months ended September 30, 2025, from $46.5 million during the nine months ended September 30, 2024. The increase in net cash provided by operating activities is primarily due to higher cash receipts from customers during the period, resulting in a reduction to our days sales outstanding ("DSO"). Our DSO was 33 days for the third quarter of 2025 compared to 37 days for the third quarter of 2024. The Company calculates DSO by dividing the average accounts receivable balance for the quarter by average daily revenues for the quarter. The Company's primary sources of cash were receipts generated from the sales of our products and services. The primary uses of cash to fund operations included personnel expenses, sales commissions, royalty payments, payments for contract labor and other direct expenses associated with delivery of our products and services, income tax payments, general corporate expenses, and initial direct costs related to the sublease discussed above.

Net cash used in investing activities was $27.0 million for the nine months ended September 30, 2025, compared to $25.9 million for the nine months ended September 30, 2024. During the nine months ended September 30, 2025, the Company invested in marketable securities of $41.4 million, made payments for capitalized software development of $21.9 million, purchased property and equipment of $3.5 million, and purchased strategic investments of $1.5 million. These uses of cash were partially offset by $41.3 million in maturities of marketable securities. During the nine months ended September 30, 2024, the Company invested in marketable securities of $51.5 million, made payments for capitalized software development of $20.1 million, and purchased property and equipment of $1.2 million. These uses of cash were partially offset by $46.2 million in maturities of marketable securities and $0.8 million received upon the settlement and release of escrowed proceeds related to a prior sale of a non-marketable equity investment.

Net cash used in financing activities was $29.0 million for the nine months ended September 30, 2025, compared to $3.5 million for the nine months ended September 30, 2024. The uses of cash for the nine months ended September 30, 2025 included $25.0 million for repurchases of common stock, $2.8 million for the payment of cash dividends, and $1.2 million for the payment of employee payroll taxes in relation to the vesting of restricted share units. The uses of cash for the nine months ended September 30, 2024 included $2.6 million for the payment of cash dividends and $0.9 million for the payment of employee payroll taxes in relation to the vesting of restricted share units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16

------

[**Table of Contents**](#toc)

Our balance sheet reflects working capital of $35.1 million at September 30, 2025, compared to $37.4 million at December 31, 2024. The decrease in working capital is primarily a result of a decrease in cash and cash equivalents to fund share repurchases. The Company's primary source of liquidity as of September 30, 2025 was $53.5 million of cash and cash equivalents and $39.0 million of marketable securities.

The Company also has a $50.0 million revolving credit facility, the availability of which is subject to certain covenants and minimum liquidity requirements. There currently are no outstanding borrowings under the revolving credit facility. The revolving credit facility expires on October 6, 2026, unless earlier renewed or amended. For additional information regarding our revolving credit facility, see Note 8 to the Condensed Consolidated Financial Statements included herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On February 20, 2023, we announced that our Board approved a quarterly dividend policy, under which we have paid dividends on a quarterly basis since our adoption of this policy. On February 24, 2025, the Board approved a quarterly cash dividend under this policy of $0.031 per share, which was paid on March 21, 2025 to holders of record of our common stock on March 10, 2025. On May 5, 2025, the Board approved a quarterly cash dividend under this policy of $0.031 per share, which was paid on May 30, 2025 to holders of record of our common stock on May 19, 2025. On August 4, 2025, the Board approved a quarterly cash dividend under this policy of $0.031 per share, which was paid on August 29, 2025 to holders of record of our common stock on August 18, 2025. In addition, on November 3, 2025, the Board approved a quarterly cash dividend under this policy of $0.031 per share, which will be payable on November 28, 2025 to holders of record of our common stock on November 17, 2025.

The dividend policy and the declaration and payment of each quarterly cash dividend will be subject to our Board's continuing determination that the policy and the declaration and payment of dividends thereunder are in the best interests of our shareholders and are in compliance with applicable law and our credit agreement. Our Board retains the power to modify, suspend, or cancel the dividend policy and quarterly dividends thereunder in any manner and at any time that our Board may deem necessary or appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On September 13, 2023, the Company announced a share repurchase program authorized by the Company's Board of Directors under which the Company was authorized to purchase up to $10.0 million of its common stock. Pursuant to this authorization, repurchases could be made in the open market, including under a Rule 10b5-1 plan, through privately negotiated transactions, or otherwise. Under this program, during 2023, the Company repurchased 404,188 shares of common stock at an aggregate fair value of $8.9 million, reflecting an average price per share of $22.07 (excluding the cost of broker commissions). The share repurchase program expired according to its terms on March 31, 2024, and no repurchases occurred under such program during 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On May 8, 2025, the Company's Board of Directors approved a new share repurchase program for the Company's common stock, under which the Company was authorized to repurchase up to $25.0 million of outstanding shares of common stock. Pursuant to this authorization, the Company was authorized to make repurchases in the open market, including under a Rule 10b5-1 plan, through privately negotiated transactions, or otherwise. Under this program, during the three and nine months ended September 30, 2025, the Company repurchased 255,833 shares and 905,786 shares of common stock at an aggregate fair value of $6.9 million and $25.0 million, respectively, reflecting an average price per share of $26.94 and $27.60 (excluding the cost of broker commissions), respectively. This share repurchase program is no longer in effect as the maximum dollar amount under this program was expended during the three months ended September 30, 2025 as referenced above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We believe that our existing cash, cash equivalents, marketable securities, cash generated from operations, and available borrowings under our revolving credit facility will be sufficient to meet anticipated working capital needs, new product development, pay our quarterly dividends, any share repurchases we may elect to make under any future share repurchase program, and fund capital expenditures for at least the next 12 months and for the foreseeable future thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company's growth strategy includes acquiring businesses or making strategic investments in businesses that complement or enhance our business. It is anticipated that future acquisitions or strategic investments, if any, would be effected through cash consideration, stock consideration, debt, or a combination thereof. The issuance of our stock as consideration for an acquisition or to raise additional capital could have a dilutive effect on earnings per share and could adversely affect our stock price. Our revolving credit facility contains financial covenants and availability calculations designed to set a maximum leverage ratio of outstanding debt to consolidated EBITDA (as defined in our credit facility) and an interest coverage ratio of consolidated EBITDA to interest expense. Therefore, the maximum borrowings against our new revolving credit facility would be dependent on the covenant calculations at the time of borrowing. As of September 30, 2025, we were in compliance with all covenants under our revolving credit facility. There can be no assurance that amounts available for borrowing under our revolving credit facility will be sufficient to consummate any possible acquisitions, and we cannot provide assurance that if we need additional financing, it will be available on terms favorable to us or at all. Failure to generate sufficient cash flow from operations or raise additional capital when required in sufficient amounts and on terms acceptable to us could harm our business, financial condition, and results of operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17

------

[**Table of Contents**](#toc)

**Item 3. *Quantitative and Qualitative Disclosures about Market Risk*** 

The Company is exposed to market risk from changes in interest rates, foreign currency risk, and investment risk. We do not have any commodity price risk.

**Interest Rate Risk**

As of September 30, 2025, and during the three months then ended, the Company had no outstanding debt. We may become subject to interest rate market risk associated with any future borrowings under our revolving credit facility. The interest rate under the revolving credit facility varies depending on the interest rate option selected by the Company plus a margin determined in accordance with a pricing grid. We are also exposed to market risk with respect to our cash and investment balances, which were $92.6 million at September 30, 2025. Assuming a hypothetical 10% decrease in interest rates for invested balances, interest income from cash and investments would decrease on an annualized basis by $0.3 million.

**Foreign Currency Risk**

We have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the US dollar, including Canadian dollar, New Zealand dollar, and Australian dollar. Increases or decreases in our foreign-denominated revenue from movements in foreign exchange rates are often partially offset by the corresponding increases or decreases in our foreign-denominated operating expenses.

To the extent that our international operations grow, our risks associated with fluctuation in currency rates will become greater, and we will continue to assess our approach to managing this risk. In addition, currency fluctuations or a weakening US dollar can increase the costs of our international operations. To date, we have not entered into any foreign currency hedging contracts although we may do so in the future.

**Investment Risk**

The Company's investment policy and strategy is focused on investing in highly rated securities with the objective of minimizing the potential risk of principal loss. The Company's policy limits the amount of credit exposure to any single issuer and sets limits on the average portfolio maturity.

We have an investment portfolio that includes strategic investments in privately held companies, which primarily include early-stage companies. We primarily invest in healthcare technology companies that we believe can help expand our ecosystem. We may continue to make these types of strategic investments as opportunities arise that we find attractive. We may experience additional volatility to our Condensed Consolidated Financial Statements due to changes in market prices, observable price changes, and impairments to our strategic investments. These changes could be material based on market conditions and events.

The above market risk discussion and the estimated amounts presented are forward-looking statements of market risk assuming the occurrence of certain adverse market conditions. Actual results in the future may differ materially from those projected as a result of actual developments in the market.

**Item 4. *Controls and Procedures***

**Evaluation of Controls and Procedures**

HealthStream's chief executive officer and principal financial officer have reviewed and evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act")) as of the end of the period covered by this Form 10-Q. Based on that evaluation, the chief executive officer and principal financial officer have concluded that HealthStream's disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and the information required to be disclosed in the reports the Company files or submits under the Exchange Act was accumulated and communicated to the Company's management, including its chief executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

**Changes in Internal Control over Financial Reporting**

There was no change in HealthStream's internal control over financial reporting that occurred during the third quarter of 2025 that has materially affected, or that is reasonably likely to materially affect, HealthStream's internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18

------

[**Table of Contents**](#toc)

**PART II** - **OTHER INFORMATION** 

**Item 1. *Legal Proceedings***

None.

**Item 1A. *Risk Factors***

There have been no material changes to the risk factors previously disclosed in Part I, Item 1A of the 2024 Form 10-K, except as set forth below:

**Risks Related to Our Business Model**

***We have been impacted, and may continue to be adversely impacted, by unfavorable conditions and uncertainty impacting the healthcare industry and the U.S. economy more generally.***

Macroeconomic conditions in the U.S. continue to be challenging in certain respects, driven by, among other things, persistent inflationary pressures, ongoing elevated interest rate levels, ongoing policy-related uncertainty, lower consumer sentiment levels compared to recent periods, heightened geopolitical tensions, including as a result of ongoing conflicts abroad and strained global trade relations. Additional challenges related to macroeconomic conditions in the U.S. that are impacting or may impact healthcare more directly include current or potential policy and regulatory decisions to reduce government funding for certain healthcare provider organizations or programs, tariff-related policies that impact goods and services on which healthcare organizations rely, and uncertainty around reduction to payment rates, including through cuts to Medicaid or other payment programs, and loss of insurance coverage by individuals. These conditions have, among other things, limited our ability to forecast future demand for our products and services, contributed to increased volatility in customer demand, and could constrain future access to capital for ourselves, our suppliers, customers, and partners. Moreover, while inflation has decreased in comparison to recent periods, we have experienced, and believe that many of our customers have experienced, increased labor, supply chain, capital, and other expenditures associated with inflationary conditions.

We sell our products and services to large, mid-sized, and small healthcare organizations whose businesses fluctuate based on general economic and business conditions. As such, our operating results may vary based on the level of demand for our solutions by healthcare organizations and the impact of changes in our industry or the economy on us or our clients. For example, we have recently experienced a decrease in demand for certain of our solutions, such as health equity and belonging content, that may be viewed as a more elective type of offering by some of our customers. In addition, a portion of our revenue is attributable to the number of users of our products at each of our clients, which in turn is influenced by the employment and hiring patterns of our clients and potential clients. To the extent that economic uncertainty or weak economic conditions cause our clients and potential clients to freeze or reduce their headcount or operations, demand for our products may be negatively affected. Moreover, current economic conditions and uncertainty have resulted in and may continue to result in overall reductions in spending by some healthcare providers as well as pressure from some clients and potential clients for extended payment terms. If current economic conditions deteriorate, our clients and potential clients may elect to decrease their budgets for our solutions by deferring or reconsidering purchases or could file for bankruptcy, which has occurred from time to time. Such budget decreases or bankruptcy filings would limit our ability to grow our business and negatively affect our operating results.

Economic, regulatory, policy, or other recent developments that adversely or disproportionately impact the healthcare industry may reduce spending on information technology by healthcare organizations and otherwise adversely affect our customer base and our financial results. Healthcare organizations continue to face labor shortages, elevated wage and operating costs, and ongoing uncertainty regarding reimbursement levels. Furthermore, the margins of many healthcare providers are modest, and potential decreases in reimbursement for healthcare costs – whether due to federal or state budgetary constraints, deficit reduction initiatives, reduction or elimination of programs such the 340B Drug Pricing Program, reduction of insurance coverage readily available to individuals, or changes to Medicare and/or Medicaid policy – may reduce the overall solvency of our customers or cause further deterioration in their financial or business condition.

In addition, the U.S. government has recently imposed or increased tariffs on imported foreign goods and may increase tariffs or impose additional tariffs. Trade policies and tariffs affecting imported medical equipment, technology components, and other healthcare-related infrastructure have the potential to increase costs for healthcare organizations, which may reduce demand for our products and adversely impact financial results.

Moreover, budget pressures at the federal and state levels have had and may continue to have a negative impact on spending for many health and human services programs, including Medicare and Medicaid, which represent significant payor sources for our customers. In particular, the federal budget reconciliation legislation enacted on July 4, 2025 includes significant policy changes that may adversely impact healthcare provider organizations, including changes that are expected to decrease access to health insurance and result in significant cuts to federal healthcare spending, particularly within the Medicaid program. Moreover, we anticipate that federal and state budget deficits combined with growing governmental healthcare expenditures will continue to place pressure on governmental healthcare programs. Any actual or potential reductions in government healthcare spending or reduction to readily available health insurance coverage for individuals could result in reduced demand for our products or heightened pricing pressure. Additionally, the federal government entered a partial shutdown effective October 1, 2025, which may result in delays in or uncertainty of payments for services rendered by our healthcare customers, which could decrease the demand for our products from such customers.

Additionally, enhanced premium tax credits for individuals eligible to purchase insurance coverage through federal and state-based health insurance marketplaces are scheduled to expire at the end of 2025, and further extension is uncertain. If these tax credits are not extended, this could reduce insurance coverage levels and indirectly influence the budgets of our healthcare customers in a manner that adversely impacts us.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19

------

[**Table of Contents**](#toc)

Further, there is ongoing uncertainty regarding the federal budget and federal spending levels, including the possible impacts of a failure to increase the "debt ceiling" and any possible U.S. governmental default on its debt. Additionally, the current presidential administration earlier this year implemented the "Department of Government Efficiency" ("DOGE"), an advisory commission focused on restructuring and streamlining government agencies and reducing or eliminating regulations and federal government programs and other expenditures, which has also given rise to separate efforts at the state level to reduce government spending. In March 2025, in accordance with the DOGE Workforce Optimization Initiative, HHS announced a significant agency restructuring, reducing the HHS workforce and consolidating divisions of the agency. Pressures on and uncertainty surrounding the U.S. federal and state annual appropriations, lapses in appropriations, holds on congressionally authorized spending, or interruptions in the distribution of governmental funds, could adversely affect our financial results due to the reliance of many of our customers on payments from third-party healthcare payors, including Medicare, Medicaid, and other government-sponsored programs.

We believe that conditions and uncertainties impacting the healthcare industry and our healthcare customers as described above have adversely affected, and may continue to adversely impact, our business and results of operations, including by lengthening sales cycles, increasing pricing sensitivity, and delaying investment decisions among our customers and potential customers. Moreover, if economic or conditions impacting the healthcare industry or U.S. economy significantly deteriorate, our results of operations, financial position, and/or cash flows could be materially and adversely affected.

**Item 2. *Unregistered Sales of Equity Securities and Use of Proceeds***

On May 8, 2025, the Company's Board of Directors approved a share repurchase program for the Company's common stock, under which the Company was authorized to repurchase up to $25.0 million of outstanding shares of common stock. Pursuant to the authorization, the Company was authorized to make repurchases in the open market, including under a Rule 10b5-1 plan, through privately negotiated transactions, or otherwise. Under this program, during the three and nine months ended September 30, 2025, the Company repurchased 255,833 shares and 905,786 shares of common stock at an aggregate fair value of $6.9 million and $25.0 million, respectively, reflecting an average price per share of $26.94 and $27.60 (excluding the cost of broker commissions), respectively. This share repurchase program is no longer in effect as the maximum dollar amount under this program was expended during the three months ended September 30, 2025 as referenced above.

The following table presents information with respect to HealthStream's repurchases of common stock during the three months ended September 30, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **(a) Total number of shares (or units) purchased** | **(b) Average price paid per share (or unit)(1)** | **(c) Total number of shares (or units) purchased as part of publicly announced plans or programs** | **(d) Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs** |
| Month #1 (July 1 - July 31) | 255833 | $26.94 | 6891813 | $— |
| Month #2 (August 1 - August 31) |  |  |  |  |
| Month #3 (September 1 - September 30) |  |  |  |  |
| Total | 255833 | $26.94 | 6891813 | $— |

---

(1) The weighted average price paid per share of common stock does not include the cost of broker commissions.

**Item *5. Other Information***

None. Without limiting the generality of the foregoing, during the *nine* months ended *September 30, 2025*, *no* director or officer of the Company adopted or terminated any "Rule *10b5*-*1* trading arrangement," or any "non-Rule *10b*-*5* trading arrangement," as such terms are defined in Item *408* of Regulation S-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20

------

[**Table of Contents**](#toc)

**Item 6. *Exhibits***

(a) Exhibits

---

| | |
|:---|:---|
| 31.1 | [Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex_854732.htm) |
| 31.2 | [Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex_854733.htm) |
| 32.1 | [Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex_854734.htm) |
| 32.2 | [Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex_854735.htm) |
| 101.1 INS | Inline XBRL Instance Document – The instant document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.1 SCH | Inline XBRL Taxonomy Extension Schema |
| 101.1 CAL | Inline XBRL Taxonomy Extension Calculation Linkbase |
| 101.1 DEF | Inline XBRL Taxonomy Extension Definition Linkbase |
| 101.1 LAB | Inline XBRL Taxonomy Extension Label Linkbase |
| 101.1 PRE | Inline XBRL Taxonomy Extension Presentation Linkbase |
| 104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, has been formatted in Inline XBRL |
| ^ | Management contract or compensatory plan or arrangement |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

------

[**Table of Contents**](#toc)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | HEALTHSTREAM, INC. | HEALTHSTREAM, INC. |
| November 6, 2025 | By: | /s/ Scott A. Roberts |
|  |  | Scott A. Roberts |
|  |  | Chief Financial Officer |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22

## Exhibit 31.1

EXHIBIT 31.1

**<u>CERTIFICATION</u>**

I, Robert A. Frist, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of HealthStream, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: November 6, 2025 | /s/ Robert A. Frist, Jr. |
|  | Robert A. Frist, Jr. |
|  | Chief Executive Officer |

---

## Exhibit 31.2

EXHIBIT 31.2

**<u>CERTIFICATION</u>**

I, Scott A. Roberts, certify that:

1. I have reviewed this quarterly report on Form 10-Q of HealthStream, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: November 6, 2025 | /s/ Scott A. Roberts |
|  | Scott A. Roberts |
|  | Chief Financial Officer |

---

## Exhibit 32.1

EXHIBIT 32.1

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of HealthStream, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Robert A. Frist, Jr., Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Robert A. Frist, Jr. |
| Robert A. Frist, Jr. |
| Chief Executive Officer |
| November 6, 2025 |

---

## Exhibit 32.2

EXHIBIT 32.2

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of HealthStream, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Scott A. Roberts, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Scott A. Roberts |
| Scott A. Roberts |
| Chief Financial Officer |
| November 6, 2025 |

---